Furthermore, since STRIVE was initiated prior to the evidence that anti-JCV antibody levels (“index”) may differentiate PML risk in natalizumab-treated MS patients without prior immunosuppressant use [11, 36], anti-JCV antibody index was not assessed in this study. Here, PML is linked to myeloid sarcoma.